Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance

Released on J-STAGE: July 12, 2022 | Article ID 22002

Ai Omi, Fumi Nomura, Shigeharu Tsujioka, Akiko Fujino, Reiko Akizuki

Candidate biomarkers for idiopathic multicentric Castleman disease

Released on J-STAGE: June 28, 2022 | Volume 62 Issue 2 Pages 85-90

Remi Sumiyoshi, Tomohiro Koga, Atsushi Kawakami

Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy

Released on J-STAGE: June 28, 2022 | Volume 62 Issue 2 Pages 91-98

Manabu Suzuki, Daisuke Koyama, Shohei Ikeda, Masumi Sukegawa, Mayumi Teshirogi, Kyohei Misawa, Saburo Tsunoda

Historical and pathological overview of Castleman disease

Released on J-STAGE: June 28, 2022 | Volume 62 Issue 2 Pages 60-72

Midori Filiz Nishimura, Yoshito Nishimura, Asami Nishikori, Tadashi Yoshino, Yasuharu Sato

Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease

Released on J-STAGE: June 28, 2022 | Volume 62 Issue 2 Pages 58-59

Naoya Nakamura